Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 112   

Articles published

JNJ 100.34 +0.20 (0.20%)
price chart
How Johnson & Johnson's BabyCenter Thinks Local by Going Global
It's a small difference, but enough of a nuance for online parenting site BabyCenter to spin out an additional week's worth of content to its French site.
Johnson & Johnson: A Dividend Growth Powerhouse In The Making? (JNJ)
Johnson & Johnson (NYSE: JNJ) currently sports a dividend with a yield of approximately 3%. For some, this may be reason enough for dividend and income investors to own the stock.
Johnson & Johnson A Good Pick For Dividend Stock (registration)
Interesting June Stock Options for Johnson & Johnson
So unless Johnson & Johnson sees its shares fall 5.2% and the contract is exercised (resulting in a cost basis of $96.30 per share before broker commissions, subtracting the $1.20 from $97.50), the only upside to the put seller is from collecting that ...
Johnson & Johnson CEO's Pay Rises 48%
Johnson & Johnson said Chairman and Chief Executive Alex Gorsky's total compensation jumped 48% to $25 million last year, lifted by an increase in stock and option awards.
Johnson & Johnson Raises Its CEO Pay By 48%  Bidness ETC
Johnson & Johnson wins Hillsborough incentives
Johnson & Johnson (NYSE: JNJ) is the second publicly identified company to bring a job creation proposal before commissioners in less than a month.
Hillsborough OKs package to lure Johnson & Johnson  WTSP 10 News
Hillsborough approves incentives for Johnson & Johnson expansion
Johnson & Johnson Vision Care Companies Launches New Beauty Innovation
"1-DAY ACUVUE� DEFINE� is the first contact lens that gives consumers a choice to not only improve their vision, but also create a more radiant eye appearance," said Laura Angelini, President, Johnson & Johnson Vision Care, Inc. "This launch is a ...
Contact Lens Makers and Discounters Tussle Over Price Setting  New York Times
Johnson & Johnson's Ethicon subsidiary reaches settlement over transvaginal ...
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Johnson & Johnson's Ethicon subsidiary reached a settlement in a bellwether trial over their transvaginal mesh devices.
Legal-Bay Lawsuit Settlement Funding Announces Transvaginal Mesh ...  MarketWatch
AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Promising Cancer Drug
For the past week, the lead bidder for Pharmacyclics was considered to be Johnson & Johnson. A deal between AbbVie and Pharmacyclics would be a remarkable turnaround for Pharmacyclics and its chief executive, Robert W. Duggan.
JOHNSON & JOHNSON  Investor's Business Daily
Biz Break: Pharmacyclics to sell in biggest biotech deal of the year ...  San Jose Mercury News
Johnson & Johnson's Zytiga May Get a Boost
We believe that Johnson & Johnson is positioned for solid growth, driven by strength of its pharmaceuticals business, recovery in the consumer segment and market stabilization coupled with share gain in medical devices and diagnostics.
Johnson & Johnson chief optimistic on China future
Johnson & Johnson chairman Alex Gorsky has urged other multinational companies to "take a long-term view" on business in China, amid an economic slowdown and international perceptions of a toughening regulatory environment in the country.